These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis. Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines. Eskander RN; Ji T; Huynh B; Wardeh R; Randall LM; Hoang B Int J Gynecol Cancer; 2013 Jul; 23(6):997-1005. PubMed ID: 23792601 [TBL] [Abstract][Full Text] [Related]
4. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of MYC attenuates tumor cell self-renewal and promotes senescence in SMARCB1-deficient Group 2 atypical teratoid rhabdoid tumors to suppress tumor growth in vivo. Alimova I; Pierce A; Danis E; Donson A; Birks DK; Griesinger A; Foreman NK; Santi M; Soucek L; Venkataraman S; Vibhakar R Int J Cancer; 2019 Apr; 144(8):1983-1995. PubMed ID: 30230537 [TBL] [Abstract][Full Text] [Related]
6. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins. Venneti S; Le P; Martinez D; Xie SX; Sullivan LM; Rorke-Adams LB; Pawel B; Judkins AR Am J Surg Pathol; 2011 Oct; 35(10):1463-72. PubMed ID: 21921784 [TBL] [Abstract][Full Text] [Related]
16. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells. Zhou W; Wang J; Man WY; Zhang QW; Xu WG Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776 [TBL] [Abstract][Full Text] [Related]
17. A kinome drug screen identifies multi-TKI synergies and ERBB2 signaling as a therapeutic vulnerability in MYC/TYR subgroup atypical teratoid rhabdoid tumors. Golbourn B; Ho B; Bondoc A; Luck A; Fan X; Richardson E; Marcellus R; Prakesch M; Halbert M; Agrawal N; Smith C; Huang A; Rutka JT Neuro Oncol; 2024 Oct; 26(10):1895-1911. PubMed ID: 38981018 [TBL] [Abstract][Full Text] [Related]
18. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239 [TBL] [Abstract][Full Text] [Related]
19. Resveratrol-induced apoptosis and increased radiosensitivity in CD133-positive cells derived from atypical teratoid/rhabdoid tumor. Kao CL; Huang PI; Tsai PH; Tsai ML; Lo JF; Lee YY; Chen YJ; Chen YW; Chiou SH Int J Radiat Oncol Biol Phys; 2009 May; 74(1):219-28. PubMed ID: 19362240 [TBL] [Abstract][Full Text] [Related]
20. OTX2 Defines a Subgroup of Atypical Teratoid Rhabdoid Tumors With Close Relationship to Choroid Plexus Tumors. Japp AS; Klein-Hitpass L; Denkhaus D; Pietsch T J Neuropathol Exp Neurol; 2017 Jan; 76(1):32-38. PubMed ID: 28025236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]